SCHEMBL1542746

SCHEMBL1542746

CNCCN(C)C=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1435246 0.83 PRMT3 (0.39)
SCHEMBL21099551 0.81 EPHX1 (0.41)
SCHEMBL18016998 0.78 PRMT3 (0.34)
SCHEMBL8746589 0.77
SCHEMBL1831649 0.77
SCHEMBL15830449 0.77
SCHEMBL16676987 0.77 PRMT3 (0.33)
SCHEMBL9814035 0.76 TSHR (0.47)
SCHEMBL4686373 0.76 PRMT3 (0.46)
SCHEMBL1829312 0.75 ADH1B (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117069747-A Method for synthesizing N-heterocyclic carbene complex by utilizing hydrolysate of imidazole salt 石河子大学 2023-11-17 CN claimed
EP-4267194-A1 TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES SOTIO Biotech a.s. (CZ) 2023-11-01 EP claimed
CN-116635085-A Tumor specific claudin 18.2 antibody-drug conjugate 斯迪安生物技术公司 2023-08-22 CN claimed
WO-2022136642-A1 TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES Sotio Biotech A.S. (CZ) 2022-06-30 WO claimed
WO-2022122709-A1 ANTIBODY-DRUG CONJUGATES BASED ON HUMANIZED CLDN18.2 ANTIBODIES Sotio Biotech A.S. (CZ) 2022-06-16 WO claimed
WO-2025078686-A1 COMBINATION THERAPY INVOLVING ANTIBODY-DRUG CONJUGATES AGAINST CLAUDIN18.2 AND PD1/PD-L AXIS INHIBITORS FOR TREATMENT OF CANCER Sotio Biotech A.S. (CZ) 2025-04-17 WO disclosed
CN-117069747-A Method for synthesizing N-heterocyclic carbene complex by utilizing hydrolysate of imidazole salt 石河子大学 2023-11-17 CN disclosed
EP-4267194-A1 TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES SOTIO Biotech a.s. (CZ) 2023-11-01 EP disclosed
WO-2023172737-A1 HETEROCYCLIC COMPOUNDS AND USES THEREOF KUMQUAT BIOSCIENCES INC. (US) 2023-09-14 WO disclosed
CN-116635085-A Tumor specific claudin 18.2 antibody-drug conjugate 斯迪安生物技术公司 2023-08-22 CN disclosed
CN-112830449-B Reversible liquid organic hydrogen storage method based on manganese catalytic hydrogenation and dehydrogenation reaction 清华大学 2022-09-27 CN disclosed
WO-2022136642-A1 TUMOR-SPECIFIC CLAUDIN 18.2 ANTIBODY-DRUG CONJUGATES Sotio Biotech A.S. (CZ) 2022-06-30 WO disclosed
CN-1708817-A Electrolytic solution for electrolytic capacitor, and method for producing tetrafluoroaluminate salt of organic onium MITSUBISHI CHEM CORP (JP) 2005-12-14 CN disclosed
US-20050222368-A1 Aqueous polyurethane dispersions LANXESS DEUTSCHLAND GMBH (DE) 2005-10-06 US disclosed
EP-1564768-A1 ELECTROLYTE FOR ELECTROLYTIC CAPACITOR, ELECTROLYTIC CAPACITOR AND PROCESS FOR PRODUCING TETRAFLUOROALUMINATE SALT OF ORGANIC ONIUM Mitsubishi Chemical Corporation (JP) 2005-08-17 EP disclosed
EP-0807105-B1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO (JP) 2004-06-16 EP disclosed
US-6284836-B1 COATINGS FOR WOOD, TEXTILE, PAPER, PLASTIC, METAL, OR LEATHER. BAYER AKTIENGESELLSCHAFT (DE) 2001-09-04 US disclosed
US-5994368-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, ANALGESICS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-11-30 US disclosed
EP-0807105-A1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-11-19 EP disclosed
WO-1996013485-A1 PYRIDOPYRIMIDONES, QUINOLINES AND FUSED N-HERETOCYCLES AS BRADYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-05-09 WO disclosed